Bronze
None
| Address | 16/17th FL., Posco Tower Yeoksam, Teheran-ro 134, Gangnam-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | 080-505-9610 | Fax | None |
| Website | www.beigene.com | hyeseon.kim@beigene.com | |
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal
Brukinsa is indicated for monotherapy treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy.
